Updated Jul 16, 2026
Collins Helen Louise has filed 4 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $4.60M.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-22 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 1.1K | $44.74 | $51K |
| 2026-06-22 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 2.6K | $43.87 | $114K |
| 2026-06-22 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 1.3K | $42.83 | $54K |
| 2026-06-22 | ELVN | Enliven Therapeutics, Inc. | M — Option exercise | 5.0K | $2.48 | $12K |
| 2026-05-20 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 223 | $41.21 | $9K |
| 2026-05-20 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 1.3K | $40.25 | $52K |
| 2026-05-20 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 3.5K | $39.53 | $137K |
| 2026-05-20 | ELVN | Enliven Therapeutics, Inc. | M — Option exercise | 5.0K | $2.48 | $12K |
| 2026-04-22 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 2.4K | $48.06 | $117K |
| 2026-04-22 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 2.4K | $47.39 | $115K |
| 2026-04-22 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale | 140 | $45.81 | $6K |
| 2026-04-22 | ELVN | Enliven Therapeutics, Inc. | M — Option exercise | 5.0K | $2.48 | $12K |
| 2026-03-27 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale [10b5-1] | 40.0K | $35.10 | $1.40M |
| 2026-03-27 | ELVN | Enliven Therapeutics, Inc. | M — Option exercise [10b5-1] | 40.0K | $2.48 | $99K |
| 2026-03-19 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale [10b5-1] | 5.0K | $27.76 | $139K |
| 2026-03-19 | ELVN | Enliven Therapeutics, Inc. | M — Option exercise [10b5-1] | 5.0K | $2.48 | $12K |
| 2026-03-11 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale [10b5-1] | 10.1K | $30.19 | $306K |
| 2026-03-11 | ELVN | Enliven Therapeutics, Inc. | M — Option exercise [10b5-1] | 10.1K | $2.48 | $25K |
| 2026-03-11 | ELVN | Enliven Therapeutics, Inc. | S — Open-market sale [10b5-1] | 29.9K | $30.02 | $897K |
| 2026-03-11 | ELVN | Enliven Therapeutics, Inc. | M — Option exercise [10b5-1] | 29.9K | $2.48 | $74K |
Collins Helen Louise is a corporate insider — currently tracked as Insider of Enliven Therapeutics, Inc. (ELVN). InsiderAlpha tracks every SEC Form 4 filing in real time.
4 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 15 open-market sales ($4.60M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Collins Helen Louise profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.